mometasonfuroat "cristers" 50 mikrogram/dosis næsespray, suspension
cristers s.a.s. - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
metformin "bluefish" 1000 mg filmovertrukne tabletter
bluefish pharmaceuticals ab - metforminhydrochlorid - filmovertrukne tabletter - 1000 mg
metformin "bluefish" 500 mg filmovertrukne tabletter
bluefish pharmaceuticals ab - metforminhydrochlorid - filmovertrukne tabletter - 500 mg
metformin "bluefish" 850 mg filmovertrukne tabletter
bluefish pharmaceuticals ab - metforminhydrochlorid - filmovertrukne tabletter - 850 mg
sterile water "fresenius kabi" solvens til parenteral anvendelse
fresenius kabi ab - vand til injektionsvÆsker - solvens til parenteral anvendelse
bicalutamide "accord" 150 mg filmovertrukne tabletter
accord healthcare b.v. - bicalutamid - filmovertrukne tabletter - 150 mg
sterilt vand "baxter" viaflo solvens til parenteral anvendelse
baxter a/s - vand, sterilt - solvens til parenteral anvendelse
adempas
bayer ag - riociguat - hypertension, lunge - antihypertensive midler til pulmonal arteriel hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har været vist i en pah befolkningen, herunder aetiologies af idiopatisk eller arvelige pah eller pah, der er forbundet med bindevævssygdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.